A5001635790- Renal cell carcinoma treatment
- Thyroid Cancer Diagnosis and Treatment
- Renal and related cancers
- Cancer Immunotherapy and Biomarkers
- Cancer Genomics and Diagnostics
- Bladder and Urothelial Cancer Treatments
- Head and Neck Anomalies
- Pancreatic and Hepatic Oncology Research
- Cervical Cancer and HPV Research
- Colorectal Cancer Treatments and Studies
- Ovarian cancer diagnosis and treatment
- Neuroendocrine Tumor Research Advances
- Urinary and Genital Oncology Studies
- Salivary Gland Tumors Diagnosis and Treatment
- Thyroid and Parathyroid Surgery
- Urological Disorders and Treatments
- CAR-T cell therapy research
- Radiomics and Machine Learning in Medical Imaging
- Genetic factors in colorectal cancer
- Brain Metastases and Treatment
- Immunotherapy and Immune Responses
- Parathyroid Disorders and Treatments
- Cancer and Skin Lesions
- Tumors and Oncological Cases
- BRCA gene mutations in cancer
Yale University
2016-2025
Beth Israel Deaconess Medical Center
2023-2024
Massachusetts General Hospital
2023-2024
The University of Texas MD Anderson Cancer Center
2007-2024
Università Cattolica del Sacro Cuore
2023-2024
Faculty of Media
2023
Koç University
2022
Roche (Switzerland)
2022
Universidad Libre de Colombia
2022
Moffitt Cancer Center
2022
Papillary carcinoma is the most common type of thyroid malignancy. It has been recently shown that these tumors commonly have one three genetic alterations: BRAF point mutations, RET/PTC rearrangements, or RAS mutations. In this study, we analyze relationship between alterations and microscopic features papillary carcinomas, their clinical features, prognostic characteristics. Ninety-seven carcinomas were studied; in all cases, frozen tissue was available for nucleic acid extraction. Of 96...
The Genitourinary Pathology Society (GUPS) undertook a critical review of the recent advances in renal neoplasia, particularly focusing on newly accumulated evidence post-2016 World Health Organization (WHO) classification. In era evolving histo-molecular classification morphology is still key. However, entities (or groups entities) are increasingly characterized by specific molecular features, often associated either with recognizable, morphologies or constellations and corresponding...
Anti-vascular endothelial growth factor therapy enhances PD-1 inhibitor activity in preclinical models and has been used to treat perilesional cerebral edema radiation necrosis. We conducted a two-institution phase II trial of bevacizumab pembrolizumab patients with untreated melanoma brain metastasis (MBM) (ClinicalTrials.gov identifier: NCT02681549). Patients were anti-PD-(L)-1-naïve, had ≥one asymptomatic, nonhemorrhagic 5-20 mm MBM, not requiring immediate local or steroids. Thirty-seven...
Abstract: Seventeen cases of granular cell tumor (GCT) the breast are reviewed. The demographics and clinical features reviewed radiologic pathologic as well immunohistochemistry discussed. To our knowledge, series 17 GCT represent largest published to date.
Pediatric renal cell carcinoma (RCC) is clinically distinct from adult RCC. Characterization of the unique biological and clinical features pediatric RCC are required.A retrospective review analysis all cases presenting to Cincinnati Children's Hospital Medical Center (CCHMC) in last 30 years was undertaken. Cases were classified according recent World Heath Organization morphologic classification TFE3/TFEB status. A literature TFE+ performed.Eleven with data identified our institutional as...
Purpose: With recent approval of inhibitors PD-1 in melanoma, non-small cell lung cancer (NSCLC) and renal carcinoma, extensive efforts are under way to develop biomarkers predictive response. PD-L1 expression has been most widely studied, is more NSCLC than carcinoma or melanoma. We therefore studied differences patterns across tumor types.Experimental Design: used tissue microarrays with tumors from NSCLC, melanoma a panel lines study between types. Predictive studies were conducted on...
Significance Parts of clear cell renal carcinomas (ccRCCs) sometimes have histologic features characteristic a sarcoma. So-called sarcomatoid tumors are more aggressive, difficult to treat, and associated with poor prognosis. Their pathogenesis has been uncertain. Through separate exome sequencing carcinomatous components, we show that these components share many somatic mutations, including in genes ccRCC. Sarcomatoid elements had significantly new particularly cancer driver genes, than...
Abstract The Bethesda 2007 Thyroid Cytology Classification defines follicular lesion of undetermined significance as a heterogeneous category cases that are not convincingly benign nor sufficiently atypical for diagnosis neoplasm or suspicious malignancy. In our institution, we refer to these indeterminate, and they further sub‐classified into two: (1) low cellularity with predominant microfollicular architecture absence colloid (IN ) (2) nuclear features characteristic lesions (nuclear...
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary point, may be published when key planned co-primary or secondary analyses are not yet available. Trial Updates provide an opportunity to disseminate additional results from studies, in JCO elsewhere, for which point has already been reported. Mesenchymal-epithelial transition (MET) signaling pathway plays a role pathogenesis of selected patients with...
<i>Background/Objective:</i> The Bethesda 2007 Thyroid Cytology Classification defines atypia of undetermined significance/follicular lesion significance (AUS/FLUS) as a heterogeneous category cases that are neither convincingly benign nor sufficiently atypical for diagnosis follicular neoplasm or suspicious malignancy. At our institution, we refer to these ‘indeterminate’ and they further subclassified into two categories. <i>BRAF</i> mutation occurs in 40–60%...
Background: The BRAF V600E mutation has been reported in 50%–80% of papillary thyroid carcinoma (PTC) cases and is highly specific for PTC. Reflex testing may improve the diagnostic accuracy fine-needle aspiration (FNA) tests having equivocal cytologic interpretations provide prognostic information that helps guide management patients with Patients Methods: Cases FNA readings (indeterminate suspicious PTC) or a positive diagnosis PTC concomitant analysis were included this prospective study....
Immunohistochemical stains have greatly improved the diagnostic accuracy of renal cell carcinoma (RCC) for primary and distant tumours. We evaluate a marker that has recently been incorporated in clinical practice, PAX-8, metastatic RCCs.Two distinct tissue microarrays were used, one consisting over 334 tumours, 294 with adjacent normal kidney other 40 matched nephrectomy sites RCC. PAX-8 expression was assessed by method quantitative immunofluorescence.PAX-8 positive 96% (146/152) 83%...
// Marina K. Baine 1 , Gabriela Turcu 2 Christopher R. Zito 1, 3 Adebowale J. Adeniran 4 Robert L. Camp Lieping Chen 5 Harriet M. Kluger * Lucia B. Jilaveanu Department of Medicine, Yale University School New Haven, CT, USA Dermatology, Carol Davila Medicine and Pharmacy, Bucharest, Romania Biology, Health Natural Sciences, Saint Joseph, West Hartford, Pathology, Immunobiology, These authors have contributed equally to this work Correspondence to: Kluger, e-mail: harriet.kluger@yale.edu...
Background: The tall cell variant of papillary thyroid carcinoma is an aggressive subtype that generally presents as a large tumor in the advanced stage; however, little known about microcarcinoma (tumors measuring <1 cm). In this study, we compare (microTCV) with classic microcarcinomas to examine hypothesis that, despite small size, microTCV may be more than microcarcinoma. Methods: We identified 27 patients and compared their clinicopathologic features BRAFV600E mutational status matched...